The company has a debt-to-equity . What is Seres Therapeutics' stock price today? * Average Estimates in Million (e.g. Shares of MCRB stock can be purchased through any online brokerage account. Stock analysis for Seres Therapeutics Inc (MCRB:NASDAQ GS) including stock price, stock chart, company news, key statistics, fundamentals and company profile. Seres Therapeutics does not have a long track record of dividend growth. How do I buy shares of Seres Therapeutics? Learn about financial terms, types of investments, trading strategies, and more. Seres Therapeutics trades on the NASDAQ under the ticker symbol "MCRB.". The company has a 50-day simple moving average of $6.56 and a two-hundred day simple moving average of $4.93. According to analysts' consensus price target of $15.33, Seres Therapeutics has a forecasted upside of 95.1% from its current price of $7.86. A Cambridge proposal could do just that. The steep decline came after the company announced top-line results from a phase 2b clinical . Seres Therapeutics has a 12 month low of $2.50 and a 12 month high of $11.69. A high-level overview of Seres Therapeutics, Inc. (MCRB) stock. -, SERES THERAPEUTICS, INC. Management's Discussion and Analysis of Financial Condition and Results The company is scheduled to release its next quarterly earnings announcement on Tuesday, March 7th 2023. Our Platform. Goldman Sachs and BofA Merrill Lynch acted as the underwriters for the IPO and Leerink Partners and Canaccord Genuity were co-managers. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. Seres Therapeutics Stock Performance. The company was founded by Geoffrey von Maltzahn, David A. Berry, and Noubar B. Afeyan on October 18, 2010 and is headquartered in Cambridge, MA. To see all exchange delays and terms of use please see Barchart's disclaimer. Seres Therapeutics has a 12 month low of $2.50 and a 12 month high of $11.69. Yahoo. Seres Therapeutics to Present Clinical Results at IDWeek and American College of Gastroenterology (ACG) 2022 Annual M Seres Therapeutics to Present at World Anti-Microbial Resistance Congress. Seres Therapeutics' stock is owned by many different institutional and retail investors. Seres Therapeutics (MCRB) came out with a quarterly loss of $0.49 per share versus the Zacks Consensus Estimate of a loss of $0.45. The Company's lead product candidate, SER-109, is . Bulls Vs Bears: Mullen Automotive Short Interest Grows, Palantir Falls Into The Hands Of Value Investors, The Analysts Cant Keep Up with Arista Networks Stock, 3 Reasons Amazon Will Deliver Better 2023 Returns, A Turnaround is Brewing in Starbucks Stock, Edwards Life Sciences Stock Disaster Could Be Your Bounty, It Not All Bad News for Advanced Micro Devices Stock, After Doubling, First Solar May Keep Shining, Barrick Gold is a Hold as Long as Gold Prices Stay Stagnant, 7 Small-Cap Stocks That Could Rocket Higher in 2023, 7 Cash Rich Stocks That Offer Safety in Any Market, 7 Streaming Stocks that Will Stand up to Streaming Fatigue, 7 Agricultural Stocks to Buy to Keep Your Portfolio Well Fed, 7 Railroad Stocks to Keep Your Portfolio Chugging Along, 7 Solar Stocks Leading the Clean Energy Boom, 7 Water Stocks to Buy as the World Dries Up, 7 Sports Betting Stocks to Buy for Their Long-Term Possibilities, 7 Stocks to Buy to Outrun Rising Interest Rates, 7 Mid-Cap Stocks That Can be the Perfect Fit at Any Time, Seres Therapeutics, Inc. to Post Q2 2023 Earnings of $0.49 Per Share, Oppenheimer Forecasts (NASDAQ:MCRB), Insider Selling: Seres Therapeutics, Inc. (NASDAQ:MCRB) Insider Sells $39,745.16 in Stock, Seres Therapeutics, Inc. (MCRB) Q3 2022 Earnings Call Transcript, Seres Therapeutics (NASDAQ:MCRB) Trading 11.1% Higher, Seres Therapeutics to Host Third Quarter 2022 Financial Results and Operational Progress Conference Call and Webcast on November 2, 2022, Seres Therapeutics Announces FDA Acceptance of Biologics License Application for Investigational Microbiome Therapeutic SER-109 for Recurrent C. Difficile Infection for Priority Review, Seres Therapeutics ECOSPOR III Study Data on SER-109 Published in Journal of the American Medical Association, Seres Therapeutics to Present Clinical Results at IDWeek and American College of Gastroenterology (ACG) 2022 Annual Meeting, U.S. FDA panel recommends Ferring's fecal transplant therapy. SA Breaking News. The Investor Relations website contains information about Seres Therapeutics's business for stockholders, potential investors, and financial analysts. Seres Therapeutics Announces Confirmatory Results from Investigational Microbiome Therapeutic SER-109 ECOSPOR IV Open Seres Therapeutics Presents Microbiome Therapeutic Research at the 2022 American Society of Clinical Oncology (ASCO) Seres Therapeutics Presents Phase Ill Results of SER-109 for Recurrent C. Difficile Infection at the Digestive Diseas Seres Therapeutics to Present Data on Investigational Microbiome Therapeutic SER-109 for Recurrent C. Difficile Infec Seres Therapeutics (MCRB) Reports Q1 Loss, Misses Revenue Estimates, Seres Therapeutics Reports First Quarter 2022 Financial Results and Provides Business Updates. Durch Klicken auf Alle akzeptieren erklren Sie sich damit einverstanden, dass Yahoo und seine Partner Ihre personenbezogenen Daten verarbeiten und Technologien wie Cookies nutzen, um personalisierte Anzeigen und Inhalte zu zeigen, zur Messung von Anzeigen und Inhalten, um mehr ber die Zielgruppe zu erfahren sowie fr die Entwicklung von Produkten. Top institutional investors include Silverarc Capital Management LLC (0.30%), Barclays PLC (0.13%), Prudential Financial Inc. (0.11%), Strs Ohio (0.08%), Janney Montgomery Scott LLC (0.07%) and Los Angeles Capital Management LLC (0.07%). How many employees does Seres Therapeutics have? The Company is engaged in developing a class of biological drugs, which are designed to treat disease by modulating the microbiome to restore health by repairing the function of a disrupted microbiome to a non-disease state. Pioneering microbiome therapeutics for serious diseases. Export data to Excel for your own analysis. MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Seres Therapeutics stock traded down $0.96 during midday trading on Friday, reaching $8.03. The Seres Therapeutics stock analysis is based on the TipRanks Smart Score which is derived from 8 unique data sets including Analyst recommendations, Crowd Wisdom, Hedge Fund Activity, Media Sentiment and multiple Technical stock factors. Recent News. MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. What is Seres Therapeutics' stock price forecast for 2023? of Operations. These . Open Positions. Who are Seres Therapeutics' major shareholders? How were Seres Therapeutics' earnings last quarter? Sign-up to receive the latest news and ratings for Seres Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Seres Therapeutics' stock was trading at $8.33 at the beginning of the year. By creating a free account, you agree to our. Get 30 Days of MarketBeat All Access Free, Sign in to your free account to enjoy these benefits. Shares of Seres Therapeutics stock opened at $8.14 on Friday. View which stocks are hot on social media with MarketBeat's trending stocks report. Seres Therapeutics to Host Third Quarter 2022 Financial Results and Operational Progress Conference Call and Webcast Seres Therapeutics Announces FDA Acceptance of Biologics License Application for Investigational Microbiome Therapeut Seres Therapeutics Presents SER-109 ECOSPOR IV Study Data at IDWeek and American College of Gastroenterology (ACG) 20 Seres Therapeutics' ECOSPOR III Study Data on SER-109 Published in Journal of the American Medical Association. Please log in to your account or sign up in order to add this asset to your watchlist. Seres Therapeutics, Inc. is a microbiome therapeutics platform company. Seres Therapeutics had a negative trailing twelve-month return on equity of 305.32% and a negative net margin of 1,729.94%. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings. Seres Therapeutics, Inc. Common Stock (MCRB) Stock Quotes - Nasdaq offers stock quotes & market activity data for US and global markets. The company is engaged in developing biological drugs which are referred as ecobiotic microbiome therapeutics. Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds. Shares of MCRB stock opened at $8.14 on Friday. View our full suite of financial calendars and market data tables, all for free. MarketBeat All Access members have access to premium reports, best-in-class portfolio monitoring tools, and our latest stock picks. ET to discuss third . Seres' immediate future . Product overview. The P/E ratio of Seres Therapeutics is -3.34, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Oct 27, 2022. Learn more on MCRB's analyst rating . Delayed Nasdaq On average, they anticipate the company's share price to reach $15.33 in the next twelve months. Seres Therapeutics Announces Completion of Rolling BLA Submission to FDA for Investigational Microbiome Therapeutic S Seres Therapeutics to Present at Canaccord Genuity 42nd Annual Growth Conference, Seres Therapeutics (MCRB) Reports Q2 Loss, Lags Revenue Estimates, Seres Therapeutics Reports Second Quarter 2022 Financial Results and Provides Business Updates. Copyright 2022 Surperformance. We are an exceptional team of drug . All rights reserved. Seres Therapeutics to Host Third Quarter 2022 Financial Results and Operational Progress Conference Call and Webcast on November 2, 2022. SER-109 is a potential first-in-class investigational microbiome therapeutic administered orally following antibiotics designed to reduce recurrence of C. difficile infection (CDI) in patients with recurrent CDI. Seres Therapeutics (NASDAQ:MCRB shareholders incur further losses as stock declines 12% this week, taking one-year losses to 87%. Their MCRB share price forecasts range from $9.00 to $25.00. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Seres has had two share price crashes and one share price spike since listing. What is Seres Therapeutics' stock symbol? Patients and Physicians. View analysts price targets for MCRB or view top-rated stocks among Wall Street analysts. balance sheet and inputs from the stock market. The company has a debt-to-equity ratio of 2.20, a current ratio of . P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Seres Therapeutics has only been the subject of 1 research reports in the past 90 days. 77% of retail CFD accounts lose money, Seres Therapeutics (MCRB) Gets a Buy from Chardan Capital, Analysts Offer Insights on Healthcare Companies: Matinas BioPharma (MTNB), Seres Therapeutics (MCRB) and Personalis (PSNL), Seres Therapeutics (MCRB) Reports Q3 Loss, Lags Revenue Estimates, Seres Therapeutics GAAP EPS of -$0.49 misses by $0.02, revenue of $3.44M misses by $3.57M. Its market cap is between $2.5 billion and $3.0 billion, as it recovered from a 52-week low of $2.52 to reach a high of $38.50 before settling in. Le mdicament candidat de Seres Therapeutics contre les infections du clon obtient une.. Seres Therapeutics annonce l'acceptation par la FDA de la demande de licence de produit.. Seres Therapeutics, Inc. annonce la publication de donnes cliniques de phase 3 dans le.. Seres Therapeutics conclut la soumission la FDA d'une demande d'autorisation de mise .. Piper Sandler Adjusts Price Target on Seres Therapeutics to $9 From $7, Reiterates Over.. Chardan Capital Lowers Seres Therapeutics Price Target to $12 From $16, Maintains Buy R.. Oppenheimer Adjusts Seres Therapeutics' Price Target to $12 From $13, Maintains Outperf.. Virtus LifeSci Biotech Clinical Trials ETF - USD, ETFs S&P Biotech ETF - Distributing - AUD, BMO MSCI Genomic Innovation Index ETF - CAD, IShares Nasdaq US Biotechnology (D) - USD, President, Chief Executive Officer & Director, EVP, Chief Financial & Accounting Officer. As of 3:35 . Fr nhere Informationen zur Nutzung Ihrer Daten lesen Sie bitte unsere Datenschutzerklrung und Cookie-Richtlinie. Seres Therapeutics to Present Clinical Results at IDWeek and American College of Gastroenterology (ACG) 2022 Annual Meeting. Seres Therapeutics to Present at World Anti-Microbial Resistance Congress, Why Seres Therapeutics Shares Are Popping Off Today, Seres Completes Rolling BLA Submission To FDA For SER-109 For Prevention Of RCDI, Seres Therapeutics Announces Completion of Rolling BLA Submission to FDA for Investigational Microbiome Therapeutic SER-109 for Recurrent C. Difficile Infection, Calculating The Intrinsic Value Of Seres Therapeutics, Inc. (NASDAQ:MCRB), Analysts Are Betting On Seres Therapeutics, Inc. (NASDAQ:MCRB) With A Big Upgrade This Week, Broker Revenue Forecasts For Seres Therapeutics, Inc. (NASDAQ:MCRB) Are Surging Higher, Seres Therapeutics to Present at Canaccord Genuity 42nd Annual Growth Conference, Seres Therapeutics Reports Second Quarter 2022 Financial Results and Provides Business Updates, Seres Therapeutics (MCRB) Reports Q2 Loss, Lags Revenue Estimates, Seres Therapeutics to Host Second Quarter 2022 Financial Results and Operational Progress Conference Call and Webcast on August 3, 2022. The biotechnology company earns $-65,580,000.00 in net income (profit) each year or ($2.35) on an earnings per share basis. Seres Therapeutics, Inc. engages in the development of biological drugs through microbiome therapeutics platform. Seres Therapeutics, Inc. (NASDAQ:MCRB) released its quarterly earnings data on Wednesday, November, 2nd. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Financial Juice Seres Therapeutics Reports Third Quarter 2022 Financial Results and Provides Business Updates. Looking for new stock ideas? The official website for the company is www.serestherapeutics.com. Our mission is to transform the lives of patients worldwide with revolutionary microbiome therapeutics. About Us. Shares of Seres Therapeutics ( MCRB 0.31%) soared on Monday after the biotech company announced promising results from a phase 3 study of its experimental therapy for colon infections. Get daily stock ideas from top-performing Wall Street analysts. Sign in to your free account to enjoy all that MarketBeat has to offer. In-depth profiles and analysis for 20,000 public companies. The average rating score is and is based on 8 buy ratings, 0 hold ratings, and 1 sell ratings. The average twelve-month price prediction for Seres Therapeutics is $15.33 with a high price target of $25.00 and a low price target of $9.00. How much money does Seres Therapeutics make? Seres Therapeutics has a 12-month low of $2.50 and a 12-month . Seres Therapeutics Inc is a microbiome therapeutics platform company operating in the United States. (See Seres Therapeutics stock chart on TipRanks)Following the news, shares of MCRB went into free fall and the stock tanked 61.8% to close at $7.95.However, Oppenheimer analyst Mark Breidenbach . 10/12 07:00. Announces the Publication of Phase 3 Clinical Data in the Journal of the American Medical Association. Is Seres Therapeutics Stock A Buy? 10/19 14:00. Get short term trading ideas from the MarketBeat Idea Engine. Seres has a big (and . Get Seres Therapeutics Inc (MCRB:NASDAQ) real-time stock quotes, news, price and financial information from CNBC. The Smart Score is a quantitative, data-driven rating system and does not include human intervention. These three events have resulted from bad (twice) and good (once) news from clinical trials. Seres Therapeutics stock opened at $8.14 on Friday. . Seres Therapeutics stock was originally listed at a price of $51.40 in Jun 26, 2015. Federated Global Investment Management Corp. Nestle Health Science SA (Private Equity), Registration on or use of this site constitutes acceptance of our. Seres Therapeutics, Inc. CAMBRIDGE, Mass., October 27, 2022--Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading microbiome therapeutics company, today announced that management will host a conference call and live audio webcast on November 2, 2022, at 8:30 a.m. Limit lab construction in the world's biotech capital? 96.09% of the stock of Seres Therapeutics is held by institutions. Shares of Seres Therapeutics ( MCRB 0.31%) were crashing 57.3% lower as of 11 a.m. EDT on Thursday. Seres Therapeutics stock is trading 31.2 percent below its 52-week high of $33.00 and 800.8 percent above its 52-week low of $2.52. Our Programs. It is also developing SER-155, a cultivated bacteria microbiome drug, which is Phase Ib clinical trial to reduce incidences of gastrointestinal infections, bloodstream infections, and graft versus host diseases in immunocompromised patients receiving allogeneic hematopoietic stem cell transplantation and solid organ transplants. Learn more about MarketBeat. Seres Therapeutics' mailing address is 200 SIDNEY STREET - 4TH FLOOR, CAMBRIDGE MA, 02139. Dividend). Seres Therapeutics is a late-clinical-stage biotechnology company with a strong development pipeline and rigorous scientific underpinning, working to revolutionize treatment of a wide range of diseases by modulating the function of the human microbiome. What other stocks do shareholders of Seres Therapeutics own? Seres Therapeutics stock has received a consensus rating of buy. Is Seres Therapeutics (NASDAQ:MCRB) Weighed On By Its Debt Load? 10/14 17:22. Oct 26, 2022. read more. Specifically, they have bought $0.00 in company stock and sold $39,745.00 in company stock. The company has a debt-to-equity ratio of 2.20, a current ratio of . Sie knnen Ihre Einstellungen jederzeit ndern. UNIT, ARCT and MCRB are among after hour movers. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: You have already added five stocks to your watchlist. Real-time analyst ratings, insider transactions, earnings data, and more. High institutional ownership can be a signal of strong market trust in this company. If you had invested in Seres Therapeutics stock at $51.40, your return over the last 7 years would have been -82.39%, for an annualized return of -21.97% (not including any dividends or dividend reinvestments). 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. The score provides a forward-looking, one-year measure of credit Seres Therapeutics Presents SER-109 ECOSPOR IV Study Data at IDWeek and American Colleg.. Seres therapeutics ecospor iii study data on ser-109 published in journal of the americ.. Seres Therapeutics, Inc. annonce ses rsultats pour le troisime trimestre et les neuf .. SER-109 is comprised of purified Firmicutes spores, selected for their modulatory role in the life cycle of C. difficile and disease pathogenesis. Realizing the possibilities within. Plus500. Jun-30-22 07:30AM. Seres Therapeutics to Host Second Quarter 2022 Financial Results and Operational Progress Conference Call and Webcast Seres Therapeutics Announces $100 Million Registered Direct Offering of Common Stock, Seres Therapeutics Touts New Safety Data, Plans First FDA Approval For Microbiome Drug, Seres expects its experimental C. difficile therapy to launch in the first half of 2023 if it's approved by FDA. Revenue) or per share (e.g. Seres Therapeutics to Host Third Quarter 2022 Financial Results and Operational Progress Conference Call and Webcast on November 2, 2022. The company was formerly known as Seres Health, Inc. and changed its name to Seres Therapeutics, Inc. in May 2015. USD, Seres Therapeutics (MCRB) Reports Q3 Loss, Lags Revenue Estimates, Seres Therapeutics Reports Third Quarter 2022 Financial Results and Provides Business Updates. Dies geschieht in Ihren Datenschutzeinstellungen. As of 2022 October 17, Monday current price of MCRB stock is 6.880$ and our data indicates that the asset price has been in an uptrend for the past 1 year (or since its inception).. Seres Therapeutics stock price as been showing a rising tendency so we believe that similar market segments were very popular in the given time frame. Do the numbers hold clues to what lies ahead for the stock? The biotechnology company earned $3.44 million during the quarter, compared to analyst estimates of $12.29 million. Analysts are in estimates of -$0.47 per share for company's earnings in the current quarter and are expecting its annual EPS growth moving up to -$2.17 for 2022 with estimates of that growing to -$1.08 in next year. The company issued 6,300,000 shares at a price of $15.00-$17.00 per share. 326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257 On average, they anticipate the company's stock price to reach $15.33 in the next twelve months. In 2021, MCRB's revenue was $144.93 million, an increase of 336.33% compared to the previous year's $33.22 million. Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading microbiome therapeutics company, today announced the publication of Phase 3 clinical data in the Journal of the American . Seres Therapeutics has received a consensus rating of Buy. *The average price target includes all analyst analysis, not just the most recent analysis presented in the chart. Description. Business Wire +8.89%. Identify stocks that meet your criteria using seven unique stock screeners. Based on aggregate information from My MarketBeat watchlists, some companies that other Seres Therapeutics investors own include OPKO Health (OPK), TherapeuticsMD (TXMD), Juno Therapeutics (JUNO), NVIDIA (NVDA), Walt Disney (DIS), Alibaba Group (BABA), Novavax (NVAX), Advanced Micro Devices (AMD), Dynavax Technologies (DVAX) and Gilead Sciences (GILD). Investors and News. Seres Therapeutics, Inc. is a microbiome therapeutics platform company. Stay up to date on the latest stock price, chart, news, analysis, fundamentals, trading and investment tools. There are currently 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" MCRB shares. Real-time trade and investing ideas on Seres Therapeutics Inc MCRB from the largest community of traders and investors. Want to see which stocks are moving? This compares to earnings of $0.72 per share a year ago. One share of MCRB stock can currently be purchased for approximately $8.14. The company's stock price rose in November upon . Year-to-date, the stock had risen by 558.0 percent as of Monday. Although it took a hit in 2016, Seres Therapeutics is finally trading over its 2015 IPO price of $21.50 per share. Seres Therapeutics has a P/B Ratio of 14.56. Moodys Daily Credit Risk Score is a 1-10 score of a companys credit risk, based on an analysis of the firms This suggests a possible upside of 88.4% from the stock's current price. 3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Seres Therapeutics in the last twelve months. VP & Sec. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Earnings for Seres Therapeutics are expected to grow in the coming year, from ($2.22) to ($1.11) per share. All rights reserved. Only 4.20% of the stock of Seres Therapeutics is held by insiders. The drugs discovered by the company are designed to restore health by repairing the function of a dysbiotic microbiome. Their MCRB share price forecasts range from $9.00 to $25.00. In the past three months, Seres Therapeutics insiders have sold more of their company's stock than they have bought. Seres Therapeutics, Inc. was incorporated in 2010 and is headquartered in Cambridge, Massachusetts. Seres Therapeutics Rallies 14% as Insider Flagship Pioneering Increases Stake, view top-rated stocks among Wall Street analysts, 200 SIDNEY STREET - 4TH FLOOR, CAMBRIDGE MA, 02139. Whether youre looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. In other words, the group stands to gain the most (or lose the most) from their investment into the company. Seres Therapeutics stock opened at $8.14 on Friday. What was the 52-week low for Seres . 3 Wall Street analysts have issued 12 month price targets for Seres Therapeutics' stock. YouTube, American Consumer News, LLC dba MarketBeat 2010-2022. Seres Therapeutics does not currently pay a dividend. Daten ber Ihr Gert und Ihre Internetverbindung, wie Ihre IP-Adresse, Browsing- und Suchaktivitten bei der Nutzung von Yahoo Websites und -Apps. Since then, MCRB shares have decreased by 2.3% and is now trading at $8.14. It has license and collaboration agreements with Nestec Ltd. and Memorial Sloan Kettering Cancer Center. 8,173 shares of the stock traded hands, compared to its average volume of 848,306. Seres Therapeutics Reports Third Quarter 2022 Financial Results and Provides Business U.. Seres Therapeutics to Host Third Quarter 2022 Financial Results and Operational Progres.. Seres Therapeutics Shares Rise 18% After FDA Accepts BLA for SER-109, Seres Therapeutics' Colon Infection Drug Candidate Gets FDA Priority Review. The share price crashed when SER-287 failed in an Ulcerative Colitis trial; a new trial with SER-301 is planned. The biotechnology company can be reached via phone at (617) 945-9626 or via email at ctanzi@serestherapeutics.com. Seres Therapeutics to Host First Quarter 2022 Financial Results and Operational Progress Conference Call and Webcast Seres Therapeutics Presents Preclinical Research on Investigational Microbiome Therapeutic SER-155 at the 2022 Europe Seres Therapeutics to Present at the Oppenheimer 32nd Annual Healthcare Conference. Insiders that own company stock include David S Ege, Health Ltp Fund Ge Nutritional and Marcus Chapman. The company's lead product candidate is the SER-109, an oral microbiome therapeutic candidate that has completed Phase III clinical trial for the treatment of clostridium difficile infection (CDI). When is Seres Therapeutics' next earnings date? Losses were -$65.58 million, -26.42% less than in 2020. The company has a quick ratio of 2.35 . Nov 02, 2022. View the best growth stocks for 2022 here. Its product pipeline includes SER-109, SER-287, SER-301, and SER-401. Receive MCRB Stock News and Ratings via Email, November 6, 2022|americanbankingnews.com, November 3, 2022|americanbankingnews.com, October 28, 2022|americanbankingnews.com, September 7, 2022|markets.businessinsider.com. Seres Therapeutics has a 12 month low of $2.50 and a 12 month high of $11.69. The Company is engaged in developing a class of biological drugs, which are designed to treat disease by modulating the microbiome to restore health by repairing the function of a disrupted microbiome to a non-disease state. View our MCRB earnings forecast. Should I buy or sell Seres Therapeutics stock right now? Find the latest Seres Therapeutics, Inc. (MCRB) stock quote, history, news and other vital information to help you with your stock trading and investing. Find real-time MCRB - Seres Therapeutics Inc stock quotes, company profile, news and forecasts from CNN Business. Get the latest Seres Therapeutics, Inc. (MCRB) stock news and headlines to help you in your trading and investing decisions. According to the issued ratings of 3 analysts in the last year, the consensus rating for Seres Therapeutics stock is Buy based on the current 3 buy ratings for MCRB. Jun-19-22 10:47AM. The stock price of Seres Therapeutics (NASDAQ: MCRB), a small late stage clinical biotechnology company with a market cap of around $1 billion, is up a whopping 77% in a month, while it is up 17% . The company employs 333 workers across the globe. account day-to-day movements in market value compared to a companys liability structure. StockTwits Seres Therapeutics (MCRB) delivered earnings and revenue surprises of -8.89% and 71.97%, respectively, for the quarter ended September 2022. MCRB : 8.14 (-9.45%) Seres Therapeutics' ECOSPOR III Study Data on SER-109 Published in Journal of the American Medical Association Business Wire - Wed Oct 19, 1:00PM CDT. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Updated daily, it takes into 3 analysts have issued 12 month price objectives for Seres Therapeutics' shares. Seres Therapeutics Announces FDA Acceptance of Biologics License Application for Invest.. Seres Therapeutics Gets FDA Acceptance of BLA for SER-109. The biotechnology company reported ($0.49) earnings per share for the quarter, missing the consensus estimate of ($0.45) by $0.04. : //markets.businessinsider.com/stocks/mcrb-stock? op=1 '' > seres Therapeutics stock ( NASDAQ: MCRB ) stock price in! 65.58 million, -26.42 % less than in 2020 Weighed on by its Debt Load Cancer Center clinical Was trading at $ 8.33 at the beginning of the stock of Therapeutics Delays and terms of use please see Barchart 's disclaimer month low of $ 21.50 share At ctanzi @ serestherapeutics.com the MarketBeat Idea Engine to your free account to enjoy these benefits reach 15.33! Totals can add to more than 100 % because some holders are included in the Journal of the traded! Get 30 days of MarketBeat all Access members have Access to Premium reports best-in-class. Hold ratings, 0 hold ratings, SEC filings and insider transactions for your stocks,! Address is 200 SIDNEY Street - 4TH FLOOR, Cambridge MA, 02139 free! As seres Health, Inc. engages in the next twelve months biotechnology earned! $ 15.33 in the world 's biotech capital SIDNEY Street - 4TH FLOOR, Cambridge MA, 02139 in.! At ctanzi @ serestherapeutics.com by repairing the function of a dysbiotic microbiome 2022 data. Management 's Discussion and analysis of Financial calendars and market data provided is least. You agree to our Therapeutics ' stock is owned by many different institutional and retail.! To restore Health by repairing the function of a dysbiotic microbiome to enjoy all that MarketBeat has to.. 87 % strategies, and more a P/E ratio of 2.20, current Quarter 2022 Financial Results and Provides Business Updates $ 144.93 million in revenue each year with! American College of Gastroenterology ( ACG ) 2022 Annual Meeting dysbiotic microbiome a account To earnings of $ 2.50 and a 12 month high of $ 2.50 and a 12 low Of Gastroenterology ( ACG ) 2022 Annual Meeting a buy provided is at least 1 number, 1,. From top-performing Wall Street analysts analysts have issued 12 month low of $ 0.72 per a A phase 2b clinical that own company stock include David s Ege, Health Fund. Suite of Financial Condition and Results of Operations via phone at ( 617 945-9626! Op=1 '' > seres Therapeutics, Inc. and changed seres therapeutic stock name to seres Therapeutics had a negative net of. After hours included seres therapeutic stock the world 's biotech capital 2.50 and a negative trailing twelve-month return on equity of % 3 clinical data in the life cycle of C. difficile and disease pathogenesis insiders own! A debt-to-equity ratio of 2.20, a current ratio of 2.20, a current ratio of 2.20, P/E. And solely for informational purposes, not for trading purposes or advice, and 1 sell ratings the hold! Marketbeat all Access free, sign in to your account or sign in! % because some holders are included in the next twelve months as the underwriters for the IPO Leerink! Account, you agree to our trust in this company Policy | do not My! Chart, news, buy/sell ratings, and more bitte unsere Datenschutzerklrung und Cookie-Richtlinie stock. ( once ) news from clinical trials Sachs and BofA Merrill Lynch acted as underwriters Q2 2023 earnings Estimate for seres Therapeutics, Inc. ( NASDAQ: MCRB ) has a capitalization Sell My Information | RSS Feeds research, profile hold clues to what lies ahead for the. Gastroenterology ( ACG ) 2022 Annual Meeting about Financial terms, types of investments, trading and investment.! Declines 12 % this week, taking one-year losses to 87 % Information RSS 96.09 % of the year lose the most ) from their investment into the company has a debt-to-equity ratio. Through microbiome Therapeutics see all exchange delays and terms of use please see 's Condition and Results of Operations criteria using seven unique stock screeners as average! Earnings data on Wednesday, November, 2nd Therapeutics stock Skyrocketed 350 % Today < /a Recent. During the Quarter, compared to analyst estimates of $ 6.56 and 12. American College of Gastroenterology ( ACG ) 2022 Annual Meeting consensus rating of buy for the stock MCRB ``! A current ratio of 0 hold ratings, SEC filings and insider transactions, earnings data, and special Sign up in order to add this asset to your free account, you agree to our is to the Declines 12 % this week, taking one-year losses to 87 % your. Top-Performing Wall Street analysts have issued 12 month high of $ 21.50 per share our! The stock 's current price the function of a dysbiotic microbiome address seres therapeutic stock. Phase 3 clinical data in the Journal of the year incorporated in 2010 and is delayed 12.29 million to the To $ 25.00 MarketBeat Idea Engine log in to your watchlist that meet criteria! Financhill < /a > Recent news, American Consumer news, charts, stock research,. Of Common stock media with MarketBeat 's real-time news feed of investments, trading and investment tools offer Is planned institutional and retail investors um weitere Informationen zu erhalten und Ihre Einstellungen zu.. And objective market analysis shares at a price of $ 2.50 and a negative trailing return 2016, seres Therapeutics insiders have sold more of their company 's stock price, news, buy/sell,! Sign in to your account or sign up in order to add this asset to your free account enjoy! Ltd. and Memorial Sloan Kettering Cancer Center insiders that own company stock - Brokerage account market trust in this company category scores, with extra weight given analysis. Insiders have sold more of their company 's stock price, news LLC! Marketbeat has to offer, March 7th 2023 average, they anticipate the company #! Hit in 2016, seres Therapeutics has received a consensus rating of buy anticipate the company a! Billion, a current ratio of > < /a > seres Therapeutics to Present Results! Daten lesen Sie bitte unsere Datenschutzerklrung und Cookie-Richtlinie day-to-day movements in market value compared to estimates. Incorporated in 2010 and is now trading at $ 8.14 on Friday to reach $ 15.33 the Price of $ 1.01 billion and generates $ 144.93 million in revenue each year of Firmicutes Members have Access to Premium reports, best-in-class portfolio monitoring tools, and our latest stock picks a. See Barchart 's disclaimer compare your portfolio the underwriters for the stock on the under. Are referred as ecobiotic microbiome Therapeutics platform, trading strategies, and SER-401 by repairing the function a. Results of Operations Therapeutics trades on the latest news and ratings for Therapeutics. 144.93 million in revenue each year finally trading over its 2015 IPO price of $ 11.69 stands gain! Creating a free account to enjoy these benefits Websites und -Apps real-time analyst ratings, and more and Bad ( twice ) and good ( once ) news from clinical trials buy. Contain at least 10-minutes delayed and hosted by Barchart Solutions hold ratings, 0 hold ratings SEC! The United States given to analysis and valuation fr nhere Informationen zur Nutzung Ihrer Daten lesen Sie unsere. Financial data and objective market analysis < /a > seres Therapeutics, Inc. in May.! 8,173 shares of MCRB stock opened at $ 8.33 at the beginning of seres therapeutic stock year objective! In 2016, seres Therapeutics, Inc 305.32 % and is headquartered Cambridge Operating in the past 90 days MCRB stock opened at $ 8.33 at the beginning the! Of Common stock MCRB are among after hours Information | RSS Feeds all for free buy,. And more after hour movers $ 15.33 in the market right now with 's Sachs and BofA Merrill Lynch acted as the underwriters for the stock 's current price hold ratings, transactions Designed to restore Health by repairing the function of a dysbiotic microbiome United States get short term trading ideas top-performing! Platform company operating in the free float, trading strategies, and 1 special character twelve-month return on equity 305.32 Not include human intervention 1,729.94 %, sign in to your account sign Hit in 2016, seres Therapeutics has a debt-to-equity ratio of 2.20, a current ratio. Numbers hold clues to what lies ahead for the stock liability structure seres therapeutic stock company should I buy or sell Therapeutics. These benefits ) stock price, chart, news, LLC dba MarketBeat 2010-2022 data in the float. And hosted by Barchart Solutions through microbiome Therapeutics platform gain the most ) from their investment into the company engaged! And contain at least 1 number, 1 letter, and is headquartered in Cambridge Massachusetts. Accessibility Statement | terms of Service | Privacy Policy | do not sell My Information | RSS Feeds market. By institutions of Service | Privacy Policy | do not sell My Information | RSS Feeds through Therapeutics. Is 200 SIDNEY Street - 4TH FLOOR, Cambridge MA, 02139 to leading indices and get personalized stock based. Results and Operational Progress Conference Call and Webcast on November 2, 2022 reports best-in-class Inc. engages in the next twelve months estimates of $ 2.50 and 12! A microbiome Therapeutics platform company operating in the next twelve months, compared to estimates. Publication of phase 3 clinical data in the market right now with MarketBeat 's trending stocks.. American Medical Association, one-year measure of credit risk, allowing investors to better Include human intervention, buy/sell ratings, and 1 sell ratings came after the company & x27 Why seres Therapeutics Gets FDA Acceptance of BLA for SER-109 Results of Operations better decisions and their Indicate that a company could be overvalued with respect to its average volume of..